Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression.

<h4>Background</h4>The response to cytotoxic chemotherapy varies greatly in patients with advanced non-small cell lung cancer (NSCLC), and molecular markers may be useful in determining a preferable therapeutic approach for individual patients. This retrospective study was performed to e...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xiaopeng Dong, Yingtao Hao, Yucheng Wei, Qiuwei Yin, Jiajun Du, Xiaogang Zhao
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/5191222fd2fd4354ac4b64cd90488992
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5191222fd2fd4354ac4b64cd90488992
record_format	dspace
spelling	oai:doaj.org-article:5191222fd2fd4354ac4b64cd904889922021-11-18T08:27:16ZResponse to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression.1932-620310.1371/journal.pone.0092320https://doaj.org/article/5191222fd2fd4354ac4b64cd904889922014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24647522/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>The response to cytotoxic chemotherapy varies greatly in patients with advanced non-small cell lung cancer (NSCLC), and molecular markers may be useful in determining a preferable therapeutic approach for individual patients. This retrospective study was performed to evaluate the predictive value of ribonucleotide reductase regulatory subunit M1 (RRM1) on the therapeutic efficacy of platinum-based chemotherapy in patients with NSCLC.<h4>Methods</h4>Patients with advanced NSCLC who received platinum doublet chemotherapy (n = 229) were included in this retrospective study, and their clinical outcomes were analyzed according to RRM1 expression.<h4>Results</h4>In patients receiving gemcitabine-based therapy, the disease control rate (DCR) and progression-free survival (PFS) of patients with RRM1-negative tumors were significantly higher than in patients with RRMI-positive tumors (P = 0.041 and P = 0.01, respectively), and multivariate analysis showed that RRM1 expression was an independent prognostic factor (P = 0.013). No similar differences were found in patients receiving docetaxel- or vinorelbine-based therapy. In RRM1-positive patients, the DCRs for docetaxel and vinorelbine were higher than for gemcitabine (P = 0.047 and P = 0.047, respectively), and docetaxel and vinorelbine showed a longer PFS than gemcitabine-based chemotherapy (P = 0.012 and P = 0.007). No similar differences were found among patients with RRM1-negative tumors.<h4>Conclusions</h4>Negative RRM1 expression in advanced NSCLC is associated with a higher response rate to gemcitabine-based chemotherapy. In patients with RRM1-positive tumors, docetaxel and vinorelbine showed a higher therapeutic efficacy than gemcitabine-based therapy. Additional prospective studies are needed to investigate the predictive meaning of RRM1 in the response to chemotherapy.Xiaopeng DongYingtao HaoYucheng WeiQiuwei YinJiajun DuXiaogang ZhaoPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 3, p e92320 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Xiaopeng Dong Yingtao Hao Yucheng Wei Qiuwei Yin Jiajun Du Xiaogang Zhao Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression.
description	<h4>Background</h4>The response to cytotoxic chemotherapy varies greatly in patients with advanced non-small cell lung cancer (NSCLC), and molecular markers may be useful in determining a preferable therapeutic approach for individual patients. This retrospective study was performed to evaluate the predictive value of ribonucleotide reductase regulatory subunit M1 (RRM1) on the therapeutic efficacy of platinum-based chemotherapy in patients with NSCLC.<h4>Methods</h4>Patients with advanced NSCLC who received platinum doublet chemotherapy (n = 229) were included in this retrospective study, and their clinical outcomes were analyzed according to RRM1 expression.<h4>Results</h4>In patients receiving gemcitabine-based therapy, the disease control rate (DCR) and progression-free survival (PFS) of patients with RRM1-negative tumors were significantly higher than in patients with RRMI-positive tumors (P = 0.041 and P = 0.01, respectively), and multivariate analysis showed that RRM1 expression was an independent prognostic factor (P = 0.013). No similar differences were found in patients receiving docetaxel- or vinorelbine-based therapy. In RRM1-positive patients, the DCRs for docetaxel and vinorelbine were higher than for gemcitabine (P = 0.047 and P = 0.047, respectively), and docetaxel and vinorelbine showed a longer PFS than gemcitabine-based chemotherapy (P = 0.012 and P = 0.007). No similar differences were found among patients with RRM1-negative tumors.<h4>Conclusions</h4>Negative RRM1 expression in advanced NSCLC is associated with a higher response rate to gemcitabine-based chemotherapy. In patients with RRM1-positive tumors, docetaxel and vinorelbine showed a higher therapeutic efficacy than gemcitabine-based therapy. Additional prospective studies are needed to investigate the predictive meaning of RRM1 in the response to chemotherapy.
format	article
author	Xiaopeng Dong Yingtao Hao Yucheng Wei Qiuwei Yin Jiajun Du Xiaogang Zhao
author_facet	Xiaopeng Dong Yingtao Hao Yucheng Wei Qiuwei Yin Jiajun Du Xiaogang Zhao
author_sort	Xiaopeng Dong
title	Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression.
title_short	Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression.
title_full	Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression.
title_fullStr	Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression.
title_full_unstemmed	Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression.
title_sort	response to first-line chemotherapy in patients with non-small cell lung cancer according to rrm1 expression.
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/5191222fd2fd4354ac4b64cd90488992
work_keys_str_mv	AT xiaopengdong responsetofirstlinechemotherapyinpatientswithnonsmallcelllungcanceraccordingtorrm1expression AT yingtaohao responsetofirstlinechemotherapyinpatientswithnonsmallcelllungcanceraccordingtorrm1expression AT yuchengwei responsetofirstlinechemotherapyinpatientswithnonsmallcelllungcanceraccordingtorrm1expression AT qiuweiyin responsetofirstlinechemotherapyinpatientswithnonsmallcelllungcanceraccordingtorrm1expression AT jiajundu responsetofirstlinechemotherapyinpatientswithnonsmallcelllungcanceraccordingtorrm1expression AT xiaogangzhao responsetofirstlinechemotherapyinpatientswithnonsmallcelllungcanceraccordingtorrm1expression
_version_	1718421800732327936

Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression.

Ejemplares similares